26 completed. 26 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Completed 26 |
Follow Japanese Encephalitis: new trials by email Literature Review of Japanese Encephalitis trials Research Report on Japanese Encephalitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam JEVAX, JECEVAX - Japanese Encephalitis | Phase 3 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 655 | 2017-09-30 | 2018-09-17 |
| Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) - Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 250 | 2015-06-01 | 2022-03-28 |
| Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea IMOJEV - Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 119 | 2013-07-11 | 2022-03-28 |
| Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects Rabies, Japanese Encephalitis, Placebo - Rabies, Japanese Encephalitis | Phase 3 | Completed | Novartis Vaccines | 661 | 2012-08-01 | 2014-12-08 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis | 552 | 2011-11-01 | 2014-03-11 |
| Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers Live attenuated Japanese encephalitis chimeric virus vaccine, Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine) - Japanese Encephalitis, Japanese Encephalitis Virus Disease | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 274 | 2011-07-01 | 2014-04-25 |
| Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country IXIARO - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 300 | 2010-12-01 | 2014-12-19 |
| Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study Blood draw, IC51 has given in the parent study IC51-322 - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 23 | 2010-10-01 | 2020-03-18 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV JE-CV Vaccine, Varicella Vaccine - Japanese Encephalitis, Varicella | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 454 | 2010-08-25 | 2022-03-28 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus - Japanese Encephalitis, Measles | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 542 | 2010-08-01 | 2014-08-15 |
| Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea JE vaccine - Japanese Encephalitis | Phase 3 | Completed | Boryung Pharmaceutical Co., Ltd | 205 | 2010-08-01 | 2014-01-30 |
| A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers Japanese encephalitis chimeric virus vaccine (JE-CV), Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®) - Encephalitis, Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2010-03-01 | 2013-12-25 |
| Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers Blood sample, JE-CV administered in Study JEC02 - Encephalitis, Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 596 | 2009-08-07 | 2017-11-29 |
| Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling IC51 - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 304 | 2008-09-01 | 2016-05-04 |
| Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines Japanese encephalitis vaccine, Japanese encephalitis vaccine (Acambis), Hepatitis A vaccine - Japanese Encephalitis, Hepatitis A | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1200 | 2008-08-01 | 2015-04-21 |
| Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis Mouse brain derived japanese encephalitis vaccine (MB-JEV), Primary and booster immunizations with MB-JEV, C) primary immunizations with Ixiaro - Japanese Encephalitis | Phase 3 | Completed | Helsinki University Central Hospital | 120 | 2008-01-01 | 2011-10-28 |
| Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51 Japanese Encephalitis purified inactivated vaccine - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 389 | 2007-12-01 | 2014-05-16 |
| Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 IC51 - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 198 | 2007-12-01 | 2014-05-16 |
| Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 IC51 - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 639 | 2006-09-01 | 2024-03-21 |
| A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX ChimeriVax™-JE, JE-VAX® - Japanese Encephalitis | Phase 3 | Completed | Sanofi | 820 | 2005-11-01 | 2012-12-06 |
Showing 20 of 26. Sign in to see all of them.
Encephalitis, Japanese (26) · Encephalitis (3) · Rabies (2) · Chickenpox (1) · Hepatitis A (1) · Measles (1) · Meningitis, Meningococcal (1) · Meningococcal Infections (1) · Mumps (1) · Rubella (1) · Typhoid Fever (1) · Yellow Fever (1)
Arbovirus Infections (26) · Brain Diseases (26) · Central Nervous System Diseases (26) · Central Nervous System Infections (26) · Central Nervous System Viral Diseases (26) · Encephalitis, Arbovirus (26) · Encephalitis, Viral (26) · Flaviviridae Infections (26) · Flavivirus Infections (26) · Infections (26) · Infectious Encephalitis (26) · Mosquito-Borne Diseases (26) · Nervous System Diseases (26) · Neuroinflammatory Diseases (26) · RNA Virus Infections (26)
Japanese Encephalitis Vaccines (4) · Blood Specimen Collection (2) · Hepatitis A Vaccines (2) · SA-14-14-2 vaccine (2) · Chickenpox Vaccine (1) · ChimeriVax (1) · Immunization, Secondary (1) · MenACWY-CRM vaccine (1) · Rabies Vaccines (1) · Saline Solution (1) · Vi polysaccharide vaccine, typhoid (1) · Yellow Fever Vaccine (1)
Valneva Austria GmbH (11) · Sanofi Pasteur, a Sanofi Company (8) · Sanofi (2) · Boryung Pharmaceutical Co., Ltd (1) · Helsinki University Central Hospital (1) · National Institute of Hygiene and Epidemiology, Vietnam (1) · Novartis (1) · Novartis Vaccines (1)
Germany (6) · Austria (4) · Philippines (4) · Australia (3) · South Korea (3) · Thailand (3) · United States (3) · Vietnam (2) · Czechia (1) · Switzerland (1) · Taiwan (1)
Astrid Kaltenboeck, Ph.D. (3) · Susanne Eder (2) · Susanne Eder, Mag. (2) · Andrea Ayad, Dr. (1) · Anu Kantele, MD PhD (1) · Eili Huhtamo, PhD (1) · Elina Erra, MD (1) · Evelyn Hatzenbichler (1) · Hoan Jong Lee, PhD (1) · Jukka Riutta, MD (1) · Lars Lindqvist, MD PhD (1) · Lars Rombo, MD PhD (1) · Luis Angles, M.D. (1)
PMID 20934459, PMID 21288804, PMID 22696017, PMID 22777096, PMID 24656175, PMID 24717964, PMID 24873986, PMID 25308927, PMID 25483480, PMID 25567119, PMID 26005163, PMID 26994987, PMID 29081368, PMID 29325161, PMID 32156630